US 11884731
Vedolizumab for the treatment of fistulizing Crohn's disease
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11884731 (Vedolizumab for the treatment of fistulizing Crohn's disease) held by Takeda Pharmaceutical Company Limited expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61P